Ras pathway inhibition prevents neovascularization by repressing endothelial cell sprouting

Journal of Clinical Investigation

Volumn 123, Issue 11, 2013, Pages 4900-4908

  Westenskow, Peter D ^a   Kurihara, Toshihide ^a   Aguilar, Edith ^a   Scheppke, Elizabeth L ^a   Moreno, Stacey K ^a   Wittgrove, Carli ^a   Marchetti, Valentina ^a   Michael, Iacovos P ^b   Anand, Sudarshan ^c   Nagy, Andras ^b   Cheresh, David ^c   Friedlander, Martin ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANTAGOMIR; MICRORNA 132; PROTEIN; PROTEIN P120RASGAP; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; ENDOTHELIUM CELL SPROUTING; EYE DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAS PATHWAY; SIGNAL TRANSDUCTION; VISUAL IMPAIRMENT;

EID: 84887473221     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI70230     Document Type: Article

References (38)

1. Kurihara T, Westenskow PD, Bravo S, Aguilar E, Friedlander M. Targeted deletion of Vegfa in adult mice induces vision loss. J Clin Invest. 2012; 122(11):4213-4217.
2. Saint-Geniez M, Kurihara T, Sekiyama E, Maldonado AE, D'Amore PA. An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. Proc Natl Acad Sci U S A. 2009; 106(44):18751-18756.
3. Eremina V, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008; 358(11):1129-1136.
4. Dorrell MI, Aguilar E, Friedlander M. Retinal vascular development is mediated by endothelial filopodia, a preexisting astrocytic template and specific R-cadherin adhesion. Invest Ophthalmol Vis Sci. 2002;43(11):3500-3510.
5. Gerhardt H, et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol. 2003;161(6):1163-1177.
6. Mazzone M, et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell. 2009; 136(5):839-851.
7. Jakobsson L, et al. Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting. Nat Cell Biol. 2010;12(10):943-953.
8. Lu X, et al. The netrin receptor UNC5B mediates guidance events controlling morphogenesis of the vascular system. Nature. 2004;432(7014):179- 186.
9. Siekmann AF, Lawson ND. Notch signalling limits angiogenic cell behaviour in developing zebrafish arteries. Nature. 2007;445(7129):781-784.
10. Suchting S, et al. The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching. Proc Natl Acad Sci U S A. 2007; 104(9):3225-3230.
11. Meadows KN, Bryant P, Pumiglia K. Vascular endothelial growth factor induction of the angiogenic phenotype requires Ras activation. J Biol Chem. 2001;276(52):49289-49298.
12. McCormick F. ras GTPase activating protein: signal transmitter and signal terminator. Cell. 1989; 56(1):5-8.
13. Henkemeyer M, et al. Vascular system defects and neuronal apoptosis in mice lacking Ras GTPase-activating protein. Nature. 1995;377(6551):695-701.
14. Boon LM, Mulliken JB, Vikkula M. RASA1: variable phenotype with capillary and arteriovenous malformations. Curr Opin Genet Dev. 2005;15(3):265-269.
15. Eerola I, et al. Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations. Am J Hum Genet. 2003;73(6):1240-1249.
16. Revencu N, et al. Parkes Weber syndrome, vein of Galen aneurysmal malformation, and other fastflow vascular anomalies are caused by RASA1 mutations. Hum Mutat. 2008;29(7):959-965.
17. Stahl A, et al. The mouse retina as an angiogenesis model. Invest Ophthalmol Vis Sci. 2010; 51(6):2813-2826.
18. Larrivee B, et al. Activation of the UNC5B receptor by Netrin-1 inhibits sprouting angiogenesis. Genes Dev. 2007;21(19):2433-2447.
19. Dorrell MI, et al. Antioxidant or neurotrophic factor treatment preserves function in a mouse model of neovascularization-associated oxidative stress. J Clin Invest. 2009;119(3):611-623.
20. Heckenlively JR, et al. Mouse model of subretinal neovascularization with choroidal anastomosis. Retina. 2003;23(4):518-522.
21. Le YZ, et al. Inducible expression of cre recombinase in the retinal pigmented epithelium. Invest Ophthalmol Vis Sci. 2008;49(3):1248-1253.
22. Anand S, et al. MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nat Med. 2010; 16(8):909-914.
23. Cao J, et al. A subretinal matrigel rat choroidal neovascularization (CNV) model and inhibition of CNV and associated inflammation and fibrosis by VEGF trap. Invest Ophthalmol Vis Sci. 2010; 51(11):6009-6017.
24. Jung K, et al. Double anti-angiogenic and anti-inflammatory protein Vα targeting VEGF-A and TNF-α in retinopathy and psoriasis. J Biol Chem. 2011;286(16):14410-14418.
25. Lutty GA, McLeod DS, Bhutto I, Wiegand SJ. Effect of VEGF trap on normal retinal vascular development and oxygen-induced retinopathy in the dog. Invest Ophthalmol Vis Sci. 2011;52(7):4039-4047.
26. Brown DM, et al. Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration. Ophthalmology. 2011;118(6):1089-1097.
27. Stewart MW, Grippon S, Kirkpatrick P. Aflibercept. Nat Rev Drug Discov. 2012;11(4):269-270.
28. Batchelor TT, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11(1):83-95.
29. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008; 8(8):592-603.
30. Dorrell MI, Aguilar E, Scheppke L, Barnett FH, Friedlander M. Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. Proc Natl Acad Sci U S A. 2007;104(3):967-972.
31. Banin E, et al. T2-TrpRS inhibits preretinal neovascularization and enhances physiological vascular regrowth in OIR as assessed by a new method of quantification. Invest Ophthalmol Vis Sci. 2006; 47(5):2125-2134.
32. Wanet A, Tacheny A, Arnould T, Renard P. miR-212/132 expression and functions: within and beyond the neuronal compartment. Nucleic Acids Res. 2012;40(11):4742-4753.
33. Smith LE, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35(1):101-111.
34. Connor KM, et al. Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. Nat Protocols. 2009;4(11):1565-1573.
35. Weidemann A, et al. Astrocyte hypoxic response is essential for pathological but not developmental angiogenesis of the retina. Glia. 2010; 58(10):1177-1185.
36. Holash J, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A. 2002;99(17):11393-11398.
37. Koh YJ, et al. Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. Cancer Cell. 2010;18(2):171-184.
38. Li Z, Michael IP, Zhou D, Nagy A, Rini JM. Simple piggyBac transposon-based mammalian cell expression system for inducible protein production. Proc Natl Acad Sci U S A. 2013;110(13):5004-5009.